JP2017536414A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017536414A5 JP2017536414A5 JP2017545861A JP2017545861A JP2017536414A5 JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5 JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017545861 A JP2017545861 A JP 2017545861A JP 2017536414 A5 JP2017536414 A5 JP 2017536414A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- seq
- acid sequence
- amino acid
- vegf
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201462084003P | 2014-11-25 | 2014-11-25 | |
| US62/084,003 | 2014-11-25 | ||
| US201562147232P | 2015-04-14 | 2015-04-14 | |
| US62/147,232 | 2015-04-14 | ||
| US14/943,490 | 2015-11-17 | ||
| US14/943,490 US20160144025A1 (en) | 2014-11-25 | 2015-11-17 | Methods and formulations for treating vascular eye diseases |
| PCT/US2015/061543 WO2016085750A1 (en) | 2014-11-25 | 2015-11-19 | Methods and formulations for treating vascular eye diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Division JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017536414A JP2017536414A (ja) | 2017-12-07 |
| JP2017536414A5 true JP2017536414A5 (enExample) | 2018-12-27 |
Family
ID=56009149
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017545861A Pending JP2017536414A (ja) | 2014-11-25 | 2015-11-19 | 血管性眼疾患を処置するための方法および製剤 |
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020201473A Pending JP2021046431A (ja) | 2014-11-25 | 2020-12-04 | 血管性眼疾患を処置するための方法および製剤 |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US20160144025A1 (enExample) |
| EP (1) | EP3224278A4 (enExample) |
| JP (2) | JP2017536414A (enExample) |
| KR (1) | KR20170087950A (enExample) |
| CN (1) | CN107001457A (enExample) |
| AU (1) | AU2015353838A1 (enExample) |
| BR (1) | BR112017009807A2 (enExample) |
| CA (1) | CA2968522A1 (enExample) |
| CL (1) | CL2017001188A1 (enExample) |
| CO (1) | CO2017004715A2 (enExample) |
| EA (1) | EA201791168A1 (enExample) |
| IL (1) | IL252159B (enExample) |
| MA (2) | MA41028A (enExample) |
| MX (1) | MX2017006129A (enExample) |
| PE (1) | PE20170900A1 (enExample) |
| PH (1) | PH12017500834A1 (enExample) |
| SG (1) | SG11201703609UA (enExample) |
| WO (1) | WO2016085750A1 (enExample) |
Families Citing this family (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3142945A1 (en) | 2005-03-25 | 2006-10-05 | Regeneron Pharmaceuticals, Inc. | Histidine-buffered formulations of vegf antagonist |
| ES2828739T3 (es) | 2006-04-07 | 2021-05-27 | Aerpio Pharmaceuticals Inc | Anticuerpos que se unen a la proteína tirosina fosfatasa beta humana (HPTP-beta) y sus usos |
| CA2654510C (en) | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US7622593B2 (en) | 2006-06-27 | 2009-11-24 | The Procter & Gamble Company | Human protein tyrosine phosphatase inhibitors and methods of use |
| BRPI1006897A2 (pt) | 2009-07-06 | 2015-09-08 | Akebia Therapeutics Inc | compostos, composições e métodos de prevenção da metástase de células cancerosas. |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| MX363351B (es) | 2011-10-13 | 2019-03-20 | Aerpio Therapeutics Inc | Un agente de unión a hptp?-ecd para usarse en el tratamiento de síndrome de fuga vascular. |
| EP2958580B8 (en) | 2013-02-21 | 2026-01-14 | RSEM, Limited Partnership | Inhibition of sema3a in the prevention and treatment of ocular hyperpermeability |
| US20150050277A1 (en) | 2013-03-15 | 2015-02-19 | Aerpio Therapeutics Inc. | Compositions and methods for treating ocular diseases |
| US11104730B2 (en) | 2013-11-20 | 2021-08-31 | Regeneren Pharmaceuticals, Inc. | Methods of treating eye disorders with APLNR antagonists and VEGF inhibitors |
| WO2015138882A1 (en) | 2014-03-14 | 2015-09-17 | Aerpio Therapeutics, Inc. | Hptp-beta inhibitors |
| WO2015200905A2 (en) | 2014-06-28 | 2015-12-30 | Oligasis, Llc | Dual pdgf/vegf antagonists |
| TWI806150B (zh) | 2014-11-07 | 2023-06-21 | 瑞士商諾華公司 | 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物 |
| CA2981021C (en) * | 2015-03-26 | 2020-11-17 | Eyekor, Llc | Image analysis |
| CN113713101B (zh) | 2015-09-23 | 2023-07-28 | 视点制药公司 | 用tie-2的激活剂治疗眼内压的方法 |
| IL290457B2 (en) | 2015-12-30 | 2025-02-01 | Kodiak Sciences Inc | Antibodies and their conjugates |
| SG10201912556VA (en) | 2016-07-20 | 2020-02-27 | Aerpio Therapeutics Inc | HUMANIZED MONOCLONAL ANTIBODIES THAT TARGET VE-PTP (HPTP-ß) |
| US20200056186A1 (en) | 2016-09-22 | 2020-02-20 | Rsem, Limited Partnership | Compositions comprising sasp modulators and senescence attenuators and uses thereof for modulating cellular senescence |
| WO2018070390A1 (ja) * | 2016-10-12 | 2018-04-19 | 第一三共株式会社 | 抗ｒｏｂｏ４抗体と他剤を含む組成物 |
| MX389729B (es) * | 2017-05-06 | 2025-03-20 | Regeneron Pharma | Uso de antagonistas de aplnr e inhibidores de vegf para tratar trastornos oculares. |
| EP4650360A3 (en) | 2017-08-18 | 2026-02-18 | Regeneron Pharmaceuticals, Inc. | Image capillary isoelectric focusing to analyze protein variants in a sample matrix |
| KR20200093621A (ko) * | 2017-11-30 | 2020-08-05 | 리제너론 파아마슈티컬스, 인크. | 혈관형성 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| EP3730126B1 (en) * | 2017-12-22 | 2025-05-14 | Samsung Bioepis Co., Ltd. | Liquid composition comprising vegf antagonist |
| US11524053B2 (en) | 2018-01-26 | 2022-12-13 | The Regents Of The University Of California | Methods and compositions for treatment of angiogenic disorders using anti-VEGF agents |
| CN111699004A (zh) * | 2018-02-06 | 2020-09-22 | 豪夫迈·罗氏有限公司 | 眼科疾病的治疗 |
| CA3092588A1 (en) | 2018-03-02 | 2019-09-06 | Kodiak Sciences Inc. | Il-6 antibodies and fusion constructs and conjugates thereof |
| WO2019173767A1 (en) * | 2018-03-08 | 2019-09-12 | Coherus Biosciences Inc. | Stable aqueous formulations of aflibercept |
| US11426446B2 (en) | 2018-03-08 | 2022-08-30 | Coherus Biosciences, Inc. | Stable aqueous formulations of aflibercept |
| CN108671229B (zh) * | 2018-05-08 | 2022-03-25 | 华博生物医药技术（上海）有限公司 | 一种重组人血管内皮生长因子受体-抗体融合蛋白的药物组合制剂 |
| RS67656B1 (sr) | 2018-05-10 | 2026-02-27 | Regeneron Pharma | Formulacije koje sadrže visoke koncentracije fuzionog proteina vegf receptora |
| JP7249060B2 (ja) * | 2018-08-17 | 2023-03-30 | トリカン・バイオテクノロジー・カンパニー・リミテッド | 抗血管新生融合タンパク質およびその使用 |
| CN119033684A (zh) | 2018-10-29 | 2024-11-29 | 豪夫迈·罗氏有限公司 | 抗体制剂 |
| CN109598628B (zh) * | 2018-11-30 | 2022-09-20 | 平安医疗健康管理股份有限公司 | 医保欺诈行为的识别方法、装置、设备及可读存储介质 |
| CN113194993A (zh) | 2018-12-18 | 2021-07-30 | 诺华股份有限公司 | 含高浓度抗vegf抗体的蛋白质溶液配制品 |
| PE20212185A1 (es) | 2019-02-18 | 2021-11-11 | Lilly Co Eli | Formulacion de anticuerpos terapeuticos |
| JP7564824B2 (ja) | 2019-04-29 | 2024-10-09 | アイポイント ファーマシューティカルズ， インコーポレイテッド | シュレム管を標的とするＴｉｅ－２活性化物質 |
| PE20240329A1 (es) | 2019-06-05 | 2024-02-27 | Regeneron Pharma | Dispositivos y metodos para administracion de dosis de precision |
| CN110423281B (zh) * | 2019-07-31 | 2021-04-30 | 成都金唯科生物科技有限公司 | 用于治疗老年性黄斑变性的融合蛋白、病毒载体和药物 |
| CA3157509A1 (en) | 2019-10-10 | 2021-04-15 | Kodiak Sciences Inc. | Methods of treating an eye disorder |
| CN114867487A (zh) | 2019-11-25 | 2022-08-05 | 加利福尼亚大学董事会 | 用于眼内新生血管的长效vegf抑制剂 |
| CN113493519B (zh) * | 2020-03-19 | 2022-12-27 | 浙江道尔生物科技有限公司 | 一种半衰期显著延长的治疗眼部血管新生疾病的融合蛋白 |
| WO2021220138A1 (en) * | 2020-04-29 | 2021-11-04 | Novartis Ag | A computer-implemented system and method for assessing a level of activity of a disease or condition in a patient's eye |
| MX2022013812A (es) | 2020-05-08 | 2022-12-15 | Regeneron Pharma | Trampas y mini-trampas de vegf y metodos para el tratamiento de trastornos oculares y cancer. |
| CA3190173A1 (en) * | 2020-06-22 | 2021-12-30 | Innovent Biologics (Suzhou) Co., Ltd. | Anti-ang-2 antibody and use thereof |
| EP4186492B1 (en) * | 2020-07-24 | 2026-01-21 | Pangen Biotech Inc. | Ophthalmic liquid composition |
| FI4185318T3 (fi) | 2021-05-17 | 2025-10-13 | Regeneron Pharma | Pitkäaikaisia, suuren annoksen VEGF-antagonistihoitoja angiogeenisten silmäsairauksien hoitoon |
| US12649031B2 (en) | 2021-09-08 | 2026-06-09 | Regeneron Pharmaceuticals, Inc. | Methods for delivering agents with pre-filled syringes to minimize intraocular inflammation |
| USD1120314S1 (en) | 2022-11-30 | 2026-03-24 | Regeneron Pharmaceuticals, Inc. | Dose delivery device |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7087411B2 (en) * | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| WO2005072772A1 (en) * | 2004-01-30 | 2005-08-11 | Suomen Punainen Risti Veripalvelu | Pharmaceutical compositions |
| AR059066A1 (es) * | 2006-01-27 | 2008-03-12 | Amgen Inc | Combinaciones del inhibidor de la angiopoyetina -2 (ang2) y el inhibidor del factor de crecimiento endotelial vascular (vegf) |
| CA2654510C (en) * | 2006-06-16 | 2015-03-17 | Regeneron Pharmaceuticals, Inc. | Vegf antagonist formulations suitable for intravitreal administration |
| US8268314B2 (en) * | 2008-10-08 | 2012-09-18 | Hoffmann-La Roche Inc. | Bispecific anti-VEGF/anti-ANG-2 antibodies |
| CA2665956A1 (en) * | 2009-05-07 | 2010-11-07 | Samir Patel | Combination treatment for ocular diseases |
| EA201190273A1 (ru) * | 2009-05-28 | 2012-12-28 | Глаксо Груп Лимитед | Комбинация антагониста tnf-альфа и антагониста vegf для применения в лечении или предупреждении заболеваний глаз |
| US20120189635A1 (en) * | 2009-07-29 | 2012-07-26 | Regeneron Pharmaceuticals, Inc. | Methods for Treating or Preventing Malaria by Administering an Antibody that Specifically Binds Angiopoietin-2 (Ang-2) |
| US8980268B2 (en) * | 2009-07-29 | 2015-03-17 | Regeneron Pharamceuticals, Inc. | Methods for treating cancer by administering an anti-Ang-2 antibody |
| JO3182B1 (ar) * | 2009-07-29 | 2018-03-08 | Regeneron Pharma | مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2 |
| TWI426920B (zh) * | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗－ｖｅｇｆ／抗－ａｎｇ－２抗體 |
| KR20180023015A (ko) * | 2011-01-13 | 2018-03-06 | 리제너론 파아마슈티컬스, 인크. | 혈관신생 눈 장애를 치료하기 위한 vegf 길항제의 용도 |
| KR102063028B1 (ko) * | 2012-01-23 | 2020-01-07 | 리제너론 파아마슈티컬스, 인크. | 항-ａｎｇ2 항체를 함유하는 안정화된 제형 |
| SI3495387T1 (sl) * | 2012-07-13 | 2021-12-31 | Roche Glycart Ag | Bispecifična protitelesa proti VEGF/proti ANG-2 in njihova uporaba pri zdravljenju bolezni očesnih žil |
| DK2928921T3 (da) * | 2012-12-05 | 2021-04-19 | Novartis Ag | Sammensætninger og fremgangsmåder til antistoffer målrettet epo |
| JO3405B1 (ar) * | 2013-01-09 | 2019-10-20 | Regeneron Pharma | الأجسام المضادة لمضاد مستقبل عامل النمو المشتق من الصفائح الدموية - بيتا واستخداماتها |
| JP2016523956A (ja) * | 2013-07-11 | 2016-08-12 | ノバルティス アーゲー | 未熟児網膜症の治療におけるｖｅｇｆアンタゴニストの使用 |
| US9914769B2 (en) * | 2014-07-15 | 2018-03-13 | Kymab Limited | Precision medicine for cholesterol treatment |
| CN106062004A (zh) * | 2013-12-17 | 2016-10-26 | 科马布有限公司 | 人靶标 |
-
2015
- 2015-11-17 US US14/943,490 patent/US20160144025A1/en not_active Abandoned
- 2015-11-18 MA MA041028A patent/MA41028A/fr unknown
- 2015-11-19 BR BR112017009807A patent/BR112017009807A2/pt not_active IP Right Cessation
- 2015-11-19 MX MX2017006129A patent/MX2017006129A/es unknown
- 2015-11-19 CN CN201580063632.5A patent/CN107001457A/zh active Pending
- 2015-11-19 KR KR1020177017473A patent/KR20170087950A/ko not_active Withdrawn
- 2015-11-19 CA CA2968522A patent/CA2968522A1/en not_active Abandoned
- 2015-11-19 AU AU2015353838A patent/AU2015353838A1/en not_active Abandoned
- 2015-11-19 PE PE2017000901A patent/PE20170900A1/es unknown
- 2015-11-19 MA MA40306A patent/MA40306A1/fr unknown
- 2015-11-19 EA EA201791168A patent/EA201791168A1/ru unknown
- 2015-11-19 EP EP15862329.8A patent/EP3224278A4/en not_active Withdrawn
- 2015-11-19 WO PCT/US2015/061543 patent/WO2016085750A1/en not_active Ceased
- 2015-11-19 JP JP2017545861A patent/JP2017536414A/ja active Pending
- 2015-11-19 SG SG11201703609UA patent/SG11201703609UA/en unknown
-
2016
- 2016-12-06 US US15/370,896 patent/US20170080086A1/en not_active Abandoned
-
2017
- 2017-05-05 PH PH12017500834A patent/PH12017500834A1/en unknown
- 2017-05-08 IL IL252159A patent/IL252159B/en active IP Right Grant
- 2017-05-10 CL CL2017001188A patent/CL2017001188A1/es unknown
- 2017-05-10 CO CONC2017/0004715A patent/CO2017004715A2/es unknown
-
2018
- 2018-12-28 US US16/235,221 patent/US11071780B2/en active Active
-
2020
- 2020-12-04 JP JP2020201473A patent/JP2021046431A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021046431A (ja) | 血管性眼疾患を処置するための方法および製剤 | |
| JP6367233B2 (ja) | 抗ｐｄｇｆｒ−ベータ抗体及びそれらの使用 | |
| US9926369B2 (en) | Methods for treating hepatocellular cancer by administering an anti-Ang-2 antibody | |
| CN102549015B (zh) | 针对人血管生成素-2的高亲和力人抗体 | |
| CA2870338C (en) | Lyophilised and aqueous anti-cd40 antibody formulations | |
| JP2020114218A5 (enExample) | ||
| WO2020094122A1 (zh) | 一种TGF-β受体融合蛋白药物组合物及其用途 | |
| CN111971062A (zh) | 一种抗人pd-1的单克隆抗体制剂、联合用药物及其用途 | |
| JP2025011323A (ja) | ＶＥ－ＰＴＰ（ＨＰＴＰ－β）を標的化するヒト化モノクローナル抗体 | |
| JP2016504416A5 (enExample) | ||
| US9932397B2 (en) | VEGFA/Ang2 Compounds | |
| CN102027015A (zh) | 抗cxcr4抗体 | |
| US20160152717A1 (en) | Methods for treating dry eye disease by administering an il-6r antagonist | |
| JP2020520912A (ja) | 抗ｇｉｔｒアゴニスト抗体での癌の処置 | |
| JP2024528724A (ja) | 抗ｐｄ－１抗体医薬組成物及びその使用 | |
| JP2021507677A5 (enExample) | ||
| JP6002354B1 (ja) | Ａｎｇ２抗体 | |
| US20240425574A1 (en) | Anti-pdgf-b antibodies and pharmaceutical composition thereof | |
| JP2020518641A5 (enExample) | ||
| KR20220069076A (ko) | 항-nrp1a 항체와 안구 또는 안구 질환 치료를 위한 이의 용도 | |
| JP2019505516A (ja) | インターロイキン−１７（ｉｌ−１７）アンタゴニストを使用してざ瘡を治療する方法 | |
| EP4519317A1 (en) | Multispecific binding molecules and methods of use thereof | |
| RU2021125763A (ru) | Биспецифическое антитело, специфически связывающееся с vegf и ang2 | |
| EA049293B1 (ru) | АНТИ-Nrp1A АНТИТЕЛА И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ГЛАЗ ИЛИ ГЛАЗНЫХ ЗАБОЛЕВАНИЙ |